File Download

There are no files associated with this item.

Supplementary

Conference Paper: KEYNOTE-495/KeyImPaCT: Interim Analysis of a Randomized, Biomarker-Directed, ProgramsPhase 2 Trial of Pembrolizumab-Based Combination Therapy for Non–Small Cell Lung Cancer

TitleKEYNOTE-495/KeyImPaCT: Interim Analysis of a Randomized, Biomarker-Directed, ProgramsPhase 2 Trial of Pembrolizumab-Based Combination Therapy for Non–Small Cell Lung Cancer
Authors
Gutierrez, MLam, WSHellmann, MDGubens, MAAggarwal, CTan, DSWFelip, EChiu, WYJLee, JSYang, JCHGaron, EBFinocchiaro, GAhn, MJLuft, ALanders, GABasso, AMa, HKobie, JPalcza, JCristescu, RFong, LSnyder, AYuan, JHerbst, RS
Issue Date2021
Citation
The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021), Virtual Meeting, Washington, DC, USA, 10–14 November 2021  How to Cite?
DescriptionConcurrent Rapid Oral Abstract Presentation Session 105: Clinical - no. 457
Persistent Identifierhttp://hdl.handle.net/10722/308408

 

DC FieldValueLanguage
dc.contributor.authorGutierrez, M-
dc.contributor.authorLam, WS-
dc.contributor.authorHellmann, MD-
dc.contributor.authorGubens, MA-
dc.contributor.authorAggarwal, C-
dc.contributor.authorTan, DSW-
dc.contributor.authorFelip, E-
dc.contributor.authorChiu, WYJ-
dc.contributor.authorLee, JS-
dc.contributor.authorYang, JCH-
dc.contributor.authorGaron, EB-
dc.contributor.authorFinocchiaro, G-
dc.contributor.authorAhn, MJ-
dc.contributor.authorLuft, A-
dc.contributor.authorLanders, GA-
dc.contributor.authorBasso, A-
dc.contributor.authorMa, H-
dc.contributor.authorKobie, J-
dc.contributor.authorPalcza, J-
dc.contributor.authorCristescu, R-
dc.contributor.authorFong, L-
dc.contributor.authorSnyder, A-
dc.contributor.authorYuan, J-
dc.contributor.authorHerbst, RS-
dc.date.accessioned2021-12-01T07:52:57Z-
dc.date.available2021-12-01T07:52:57Z-
dc.date.issued2021-
dc.identifier.citationThe Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021), Virtual Meeting, Washington, DC, USA, 10–14 November 2021 -
dc.identifier.urihttp://hdl.handle.net/10722/308408-
dc.descriptionConcurrent Rapid Oral Abstract Presentation Session 105: Clinical - no. 457-
dc.languageeng-
dc.relation.ispartofThe Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs (SITC 2021)-
dc.titleKEYNOTE-495/KeyImPaCT: Interim Analysis of a Randomized, Biomarker-Directed, ProgramsPhase 2 Trial of Pembrolizumab-Based Combination Therapy for Non–Small Cell Lung Cancer-
dc.typeConference_Paper-
dc.identifier.emailChiu, WYJ: jwychiu@hku.hk-
dc.identifier.authorityChiu, WYJ=rp01917-
dc.identifier.hkuros330568-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats